chronic%20myeloid%20leukemia
CHRONIC MYELOID LEUKEMIA

Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

Surgical Intervention

Hematopoietic Stem Cell Transplantation (HSCT)
  • Patients are first treated with a preparative or conditioning regimen (eg chemotherapy or radiation therapy orboth) followed by infusion of hematopoietic progenitor/stem cells
  • Parameters for HCT application depends on the patient’s disease & stage of the disease, cell donor & the source of the progenitor cells

Allogeneic hematopoietic stem cell transplantation (Allo-HCT)

  • The indications & outcomes of allo-HCT will depend on the age & comorbidities of the patient, donor type &transplant center
  • Progenitor cells are collected from healthy persons & are used to treat hematologic neoplasms, nonmalignant marrow disorders (eg acquired & inherited), & inborn errors of metabolism
  • May be considered in patients with AP unresponsive to TKI therapy, BP following induction of TKI, relapseddisease, resistant to multiple TKIs & intolerant to TKI

Monitoring response with allo-HCT

  • In patients who attained a BCR-ABL1 0.1%-<1% (IS), patients are monitored using the QPCR-IS every 3 months for 2 years then 3-6 months thereafter
    • A QPCR assay that is positive at a much later point after transplant is associated with a lower risk of relapse
    • On follow-up, the patient may have TKIs or Omacetaxine, donor lymphocyte infusion (DLI) or Interferon/Peginterferon, or may be enrolled in a clinical trial
  • In patients who did not have a CCyR or had a relapse, the withdrawal of immune suppression should be monitored
    • A QPCR assay that is positive for BCR-ABL1 at 6-12 months after transplant is associated with a higher riskof relapse
    • On follow-up, the patient may also have TKIs or Omacetaxine, DLI or Interferon/Peginterferon, or may been rolled in a clinical trial

Management of post-transplant relapse

  • Donor lymphocyte infusion (DLI)
    • Induces effective durable molecular remissions in patients with relapsed CML following allo-HCT
      • The probability of survival at 3 years is better
  • More effective in patients with chronic phase relapse
  • Complications such as graft-vs-host disease (GVHD), susceptibility to infections & immunosuppression may develop
  • Ways on how to reduce the incidence of GVHD:
    • Improve the methods that detects BCR-ABL1 transcripts
    • Develop reduced-intensity conditioning regimens
    • Modify the delivery of lymphocytes with the depletion of CD8+ cells
    • Escalate cell dosage regimen
    • Very low-dose DLI & IFN-alpha combination may help reduce GVHD
  • Imatinib
    • Induces durable remissions in patients with relapse in all phases of CML following allo-HCT
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 28 Jun 2019
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Elaine Soliven, 18 Jun 2019
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Audrey Abella, 11 Jul 2019
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.